Fusion Pharmaceuticals IPO Presentation Deck
June 2020, 49 slides
  1. Fusion Pharmaceuticals
  2. Related Decks
  3. IPO Presentation Decks
| Fusion Pharmaceuticals
offering summary | Fusion Pharmaceuticals
forward looking statements and legal disclaimers | Fusion Pharmaceuticals
tetra overview strategy and vision | Fusion Pharmaceuticals
experienced executive team gen fey a bin a | Fusion Pharmaceuticals
creating next generation for precision oncology potent therapies simple mechanism of action platform technology | Fusion Pharmaceuticals
creating fusion pharmaceuticals | Fusion Pharmaceuticals
| Fusion Pharmaceuticals
fusion next generation for precision oncology | Fusion Pharmaceuticals
tats multiple mechanisms of action | Fusion Pharmaceuticals
fusion fast clear linker technology | Fusion Pharmaceuticals
engine with rapid development capabilities | Fusion Pharmaceuticals
use of imaging diagnostics to enrich target populations | Fusion Pharmaceuticals
established manufacturing process and supply chain core competitive advantage fast lee i multiple scale manufacturing | Fusion Pharmaceuticals
fusion platform and capabilities lead to multiple development opportunities | Fusion Pharmaceuticals
chief scientific james chief medical officer officer fusion lead program targeted alpha therapeutic | Fusion Pharmaceuticals
fusion lead program targeted alpha therapeutic | Fusion Pharmaceuticals
developing a tat targeting approximately patients received ave in i wire | Fusion Pharmaceuticals
single dose eradicated tumors in mice | Fusion Pharmaceuticals
compelling anti tumor activity across multiple tumor models and tumor sizes i with a single dose with alphas using the right | Fusion Pharmaceuticals
toxicology program assesses radiation organ exposure to bladder intestines or lung | Fusion Pharmaceuticals
james chief medical officer clinical strategy and data | Fusion Pharmaceuticals
is over expressed on multiple tumor types | Fusion Pharmaceuticals
| Fusion Pharmaceuticals
tumor uptake has been observed in different types of solid tumors on | Fusion Pharmaceuticals
repeat imaging assessment | Fusion Pharmaceuticals
cohorts and safety summary march no reported adverse events pee | Fusion Pharmaceuticals
dosimetry assessment all cohorts kidney liver lungs | Fusion Pharmaceuticals
at at | Fusion Pharmaceuticals
combination therapy programs a | Fusion Pharmaceuticals
enhanced efficacy in a mouse tumor model | Fusion Pharmaceuticals
reduced tumor growth observed in all dose groups following challenge in contralateral flank tumor mess tumor | Fusion Pharmaceuticals
infiltration of antigen specific cells is responsible for vaccine effect tumor i | Fusion Pharmaceuticals
combination of sub therapeutic single agent doses resulted in enhanced anti tumor activity sip to low dose single | Fusion Pharmaceuticals
| Fusion Pharmaceuticals
mile and us operations building on fusion platform next generation targeted alpha therapies | Fusion Pharmaceuticals
fusion is pursuing a range of opportunities to build the pipeline | Fusion Pharmaceuticals
targeting fibroblast growth factor receptor a a | Fusion Pharmaceuticals
chief financial officer finance and upcoming milestones | Fusion Pharmaceuticals
financing overview a investment perceptive poe | Fusion Pharmaceuticals
future key milestones by program | Fusion Pharmaceuticals
chief executive officer | Fusion Pharmaceuticals
creating next generation for precision oncology targeting showing uptake in multiple tumor types by | Fusion Pharmaceuticals
thank you | Fusion Pharmaceuticals
wee appendix | Fusion Pharmaceuticals
building the portfolio with key patents expiry in | Fusion Pharmaceuticals
alphas betas potency precision | Fusion Pharmaceuticals
| Fusion Pharmaceuticals
cohorts and safety summary march | Fusion Pharmaceuticals
See More
Fusion Pharmaceuticals
IPO Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Tumor
Cancer
Manufacturing
Monotherapy
Dna
Clinical trial
Recent decks by Fusion Pharmaceuticals
Investor Presentation
January 2024
Investor Presentation
November 2023
Investor Presentation
August 2023
See all presentations by Fusion Pharmaceuticals (4 decks)
Related decks
BioNTech
Results
November 2021
BioNTech
Results
May 2021
RayzeBio
IPO
September 2023
Immatics
Investor Presentation
November 2023
Mink Therapeutics
IPO
October 2021
Kiromic BioPharma
Investor Presentation
May 2023
Allarity Therapeutics
Investor Conference
September 2022
Immix Biopharma
Investor Presentation
September 2023
Recent decks by Fusion Pharmaceuticals
See all presentations (4 decks)
Investor Presentation
January 2024
Investor Presentation
November 2023
Investor Presentation
August 2023
BioNTech
Results
November 2021
BioNTech
Results
May 2021
RayzeBio
IPO
September 2023
Immatics
Investor Presentation
November 2023
Mink Therapeutics
IPO
October 2021
Kiromic BioPharma
Investor Presentation
May 2023
Allarity Therapeutics
Investor Conference
September 2022
Immix Biopharma
Investor Presentation
September 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights